Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
Displaying: 198 trials in your specialties ()
View trials across your selected specialties

Sleep and Inflammatory Resolution Pathway

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Inflammatory Response, Inflammation, Sleep Restriction, Sleep
View Full Trial
INTERVENTION

Drug: Aspirin, Drug: Placebo

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Brief Summary

Goal of this project is to investigate whether increases in inflammation that result from common patterns of restricting sleep on week nights and catching up on sleep over the weekend are caused by disruption in the newly discovered inflammatory resolution pathways. These pathways are crucial in the active termination of the inflammatory response, and their disruption may contribute to ongoing unresolved inflammation, which has been observed not only during periods of sleep restriction, but also after recovery sleep has been obtained. If the hypothesis is true, it is possible that increasing the body's natural production of endogenous, inflammatory resolution mediators may provide a non-behavioral strategy to limit the inflammatory consequences in those undergoing periods of sleep restriction with intermittent recovery sleep.

18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Neuroblastoma, Pheochromocytoma
View Full Trial
INTERVENTION

Drug: 18F-DA

Eligibility
  • Ages: 1 Year and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Brief Summary

PET (positron emission tomography) scans combined with a radioactive tracer will be used to identify and analyze tumors. Currently, the most common tracer used to analyze neuroblastoma tumors is called 123I-mIBG. However, the picture it provides is not always clear enough to see the very small areas of the disease. 18F-DA (18F-fluorodopamine) has been shown to be safe and more effective than 123I-mIBG in analyzing the tumor pheochromocytoma, which is closely related to neuroblastoma. With this research study, the investigators plan to meet the following goals: - Investigate to see if 18F-DA is safe to administer to pediatric patients with known or suspected neuroblastoma or pheochromocytoma - Examine where in the body 18F-DA goes. - Obtain information comparing 18F-DA to 123I-mIBG to see if 18F-DA could replace 123I-mIBG in the future. About 20 people, with known or suspected neuroblastoma or pheochromocytoma, will take part in this Pilot study at St. Jude.

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Total Knee Arthroplasty
View Full Trial
INTERVENTION

Drug: Oxycodone, Drug: Placebo Oral Tablet

Eligibility
  • Ages: 18 to 89 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Mayo Clinic in Florida, Jacksonville, Florida, United States

Brief Summary

To help curb the use of opioid medications following orthopedic surgery investigators have developed a new multi-modal pain pathway. Investigators aim to compare this regimen with and without the inclusion of opioid medications. This study will be performed in a randomized, double-blinded, placebo-controlled fashion in patients undergoing primary total knee or total hip arthroplasty. Investigators hypothesize that the opioid devoid pathway will show equivalent pain scores to the pathway that includes opioids while also having less constipation, nausea, and vomiting following surgery. If successful, this would create a dramatic decrease in opioid consumption following orthopedic surgery while still providing appropriate pain relief to patients.

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointes...
View Full Trial
INTERVENTION

Drug: 90Y-DOTA-3-Tyr-Octreotide, Drug: 131I-MIBG

Eligibility
  • Ages: 18 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

Brief Summary

This study is designed to identify the best tolerated doses of [131]Iodine-MIBG and [90]Yttrium-DOTATOC when co-administered to treat midgut neuroendocrine tumors. These drugs (131I-MIBG, 90Y-DOTATOC) are radioactive drugs, known as radionuclide therapy. Currently, the safest and best tolerated doses of these drugs (when combined together) is unknown.

Apremilast for RAS

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Recurrent Aphthous Stomatitis
View Full Trial
INTERVENTION

Drug: Apremilast 30mg

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Mayo Clinic in Florida, Jacksonville, Florida, United States

Brief Summary

Determination of treatment efficacy and safety of Apremilast in patients with RAS

PET Imaging CCR2 in Lung Inflammation

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Lung Inflammation
View Full Trial
INTERVENTION

Drug: 64Cu-DOTA-ECL1i

Eligibility
  • Ages: 21 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Washington University School of Medicine, Saint Louis, Missouri, United States

Brief Summary

The primary objective of this study is to determine the safety of the novel probe 64Cu-DOTA-ECL1i for PET imaging of CCR2 expression.

The Role of Neuroactive Steroids in Stress, Drug Craving and Drug Use in Cocaine Use Disorders

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Cocaine-Related Disorders
View Full Trial
INTERVENTION

Drug: PREG 300/500 mg, Drug: Placebos

Eligibility
  • Ages: 18 to 60 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Yale Stress Center, New Haven, Connecticut, United States

Brief Summary

To use pregnenolone (PREG; 300; 500mg) daily versus placebo (PLA) as a probe to assess the role of neuroactive steroids in individuals with cocaine use disorder (CUD).

An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Hidradenitis Suppurativa
View Full Trial
INTERVENTION

Drug: Brodalumab

Eligibility
  • Ages: 18 to 99 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Rockefeller University Hospital, New York, New York, United States

Brief Summary

Phase 0 Study of an alternative dosing interval of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa to identify biomarkers of disease activity and clinical response.

Serologic Response to a New Recombinant, Adjuvanted Herpes Zoster Vaccine in Patients With Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia Treated With First-Line BTK Inhibitors

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia...
View Full Trial
INTERVENTION

Drug: Shingrix vaccine

Eligibility
  • Ages: 50 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of Rochester, Rochester, New York, United States

Brief Summary

The primary objective of the study is to assess the capability of a patient with Chronic Lymphocytic Leukemia (CLL) or Waldenström Macroglobulinemia (WM) to generate an immune response to the Shingrix vaccine under first-line BTK inhibitors.

The PATHFINDER Study: A Feasibility Trial

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Coronary Artery Disease, Delirium
View Full Trial
INTERVENTION

Drug: Ropivacaine, Drug: Ketamine, Drug: Remifentanil, Drug: Dexmedetomidine, Drug: Rocuronium, Drug: Propofol, Drug: Sevoflurane, Drug: Dexmedetomidine, Drug: Propofol, Device: EEG monitoring

Eligibility
  • Ages: 60 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Brief Summary

The main purpose of this study is to determine whether a rational strategy of EEG guided multimodal general anesthesia using target specific sedative and analgesics could result in enhanced recovery after anesthesia and surgery, decrease in postoperative delirium, and decrease in long term postoperative cognitive dysfunction up to 6 months following cardiac surgery.